Zymeworks (ZYME)
(Real Time Quote from BATS)
$16.74 USD
+1.13 (7.24%)
Updated Nov 7, 2024 10:02 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ZYME 16.74 +1.13(7.24%)
Will ZYME be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZYME
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
GSK (GSK) Q3 Earnings Surpass Estimates
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Other News for ZYME
Zymeworks Launches Phase 1 Trial for ZW191
Zymeworks says first patient dosed in Phase 1 trial of ZW191
Zymeworks says first patient dosed in Phase 1 trial of ZW191
Zymeworks price target raised to $18 from $16 at Citi
Zymeworks price target raised by $2 at Citi, here's why